Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 29, 2017updated 14 Nov 2021 1:15pm

Integra to sell five neurosurgical products lines to appease FTC over J&J’s Codman deal

Integra LifeSciences and Johnson and Johnson (J&J) have decided to divest five neurosurgical medical device product lines to Natus Medical to settle a complaint filed by the Federal Trade Commission (FTC).

Integra LifeSciences and Johnson and Johnson (J&J) have decided to divest five neurosurgical medical device product lines to Natus Medical to settle a complaint filed by the Federal Trade Commission (FTC).

The complaint was filed against Integra’s proposed $1bn acquisition of J&J’s Codman Neuro division and stated that the deal would have a negative impact on neurological devices market in the US.

As per the Commission, the impacted device markets would include intracranial pressure monitoring, cerebrospinal fluid collection and fixed-pressure valve shunt systems, non-antimicrobial external ventricular drainage catheters, and dural grafts.

In the country, Integra and Codman account for 94% of the intracranial pressure monitoring systems market, 71% of the cerebrospinal fluid collection systems, 46% of the non-antimicrobial external ventricular drainage catheters, 38% for fixed pressure valve shunt systems, and 75% for dural grafts.

“The devices are expected to complement Integra’s portfolio of tissue ablation, dural repair, and cranial stabilisation products, allowing it to offer the entire range of neurosurgical solutions.”

A consent agreement signed by Integra and J&J allows the Commission to monitor compliance with the orders on divestment.

Integra and J&J entered a binding offer in February for the Codman Neurosurgery business, which includes hydrocephalus, neuro-critical care, and operative neurosurgery devices.

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

The devices are expected to complement Integra’s portfolio of tissue ablation, dural repair, and cranial stabilisation products, allowing it to offer the entire range of neurosurgical solutions.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU